Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors

• Published in: NAR cancer Vol. 3; no. 2; p. zcab018
• Main Authors: Sule, Amrita, Van Doorn, Jinny, Sundaram, Ranjini K, Ganesa, Sachita, Vasquez, Juan C, Bindra, Ranjit S
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.06.2021
• Subjects: Editor's Choice; Nucleic Acid-Based Cancer Therapeutics

Mutations in the isocitrate dehydrogenase-1 and -2 (IDH1/2) genes were first identified in glioma and acute myeloid leukemia (AML), and subsequently found in multiple other tumor types. These neomorphic mutations convert the normal product of enzyme, α-ketoglutarate (αKG), to the oncometabolite 2-hy...